Xcout Intel
Expedition Medicines
Expedition Medicines, Inc. is a biotechnology company founded in 2022 and headquartered in Cambridge, Massachusetts, focused on generatively designing novel drugs targeting specific proteins.
Subscribe to see Expedition Medicines’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Expedition Medicines at a glance
Expedition Medicines is a biotech company headquartered in United States. Xcout tracks 19 named people at Expedition Medicines, including Molly Gibson (Chief Executive Officer | Co-Founder).
Expedition Medicines leadership
- Molly GibsonChief Executive Officer | Co-Founder
- Henry van den BedemChief Technical Officer
- Dean StamosChief Scientific Officer, Proteomics & Chemistry | Co-Founder
- Nate StebbinsChief Strategy & Operations Officer | Co-Founder
- Todd KinsellaChief Scientific Officer, Drug Discovery & Translation
- Marie YurkovichHead of Strategy & Operations | Co-Founder
13 more named people on record for Expedition Medicines, with roles, board committees and tenure — see the full roster →
Expedition Medicines competitors
A few of Expedition Medicines's closest competitors — see the full list of competitors and alternatives →
Superluminal Medicines is a generative biology and chemistry company headquartered in Boston, Massachusetts, focused on drug discovery and development.
Metaphore Biotechnologies, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, operating as part of Flagship Pioneering. The company focuses on therapeutic design, leveraging AI and machine learning technologies for drug discovery and development.
Exo Therapeutics is a small molecule drug discovery and development biotechnology company headquartered in Cambridge, Massachusetts. The company utilizes a pioneering proprietary technology platform to unlock and address notoriously intractable pharmaceutical and disease targets.
Senda Biosciences is a biotechnology company focused on harnessing nature to program novel medicines, headquartered in Cambridge, Massachusetts.
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Maxion Therapeutics is a biotechnology company headquartered in Cambridge, England, utilizing proprietary KnotBody technology to discover and develop first-in-class protein therapeutics.
Get Expedition Medicines's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Expedition Medicines in Xcout Intel
- 19 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access